ArticleJournal of applied clinical medical physics2026
Quantitative analysis of robustness-based versus LET-based optimization in intensity-modulated proton therapy for pediatric brain tumors.
Article in Journal of applied clinical medical physics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Dynamic Proton arc therapy for paediatric parameningeal rhabdomyosarcoma.Journal of applied clinical medical physics · 2026Article
- Quantitative analysis of robustness-based versus LET-based optimization in intensity-modulated proton therapy for pediatric brain tumors.Journal of applied clinical medical physics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeTo perform a quantitative analysis of the trade-off between robustness-based and linear energy transfer (LET)-based optimization of intensity-modulated proton therapy for anatomically challenging pediatric brain tumor cases.
methodsThree pediatric brain tumor patients were included in this study. Three plans were generated for each case based on: (1) nominal optimization, without considering uncertainties and LET; (2) robust optimization, including proton range and patient setup uncertainties; and (3) LET optimization, considering increasing LET in the target and reducing LET in normal tissues. All plans were optimized with individually fine-tuned objective weighing to obtain highest achievable target coverage and meet dose limits of critical structures considering robustness or LET criteria. We then evaluated the impact of robust optimization on LET distribution and assessed the robustness of the LET optimization plan, intercompared with the nominal plan. We also compared the dose and LET distributions, as well as biological effect, for each individual beam across the three plans.
resultsRobust optimization consistently achieved robust target coverage among all cases, but it reduced the mean LET in the target by 8%-15% compared to nominal optimization and by 11%-20% compared to LET optimization. LET optimization was effective in reducing high LET in normal tissues. In patient cases, it reduced the maximum LET in the brainstem and spinal cord by 29%-41% and 13%-36%, respectively, compared to nominal optimization. Robust optimization also reduced high LET in the brainstem and spinal cord, but to a slightly lesser extent than LET optimization. Moreover, both robust and LET optimization resulted in less variation in the mean and maximum LETd for OARs compared to nominal optimization.
conclusionAn inherent conflict between robust target coverage and high LET in the target in IMPT planning was demonstrated in our study for pediatric brain tumor patients. Robust optimization resulted in lower LET not only in the target but also in nearby critical structures, such as brainstem and spinal cord. In contrast, LET optimization improved the LET distribution but worsened the plan robustness compared to nominal optimization. The trade-off effect between LET enhancement and plan robustness can vary in respect to anatomical relationships and needs to be carefully evaluated in IMPT planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.